Therapeutic vaccine platform to boost immune responses in Tuberculosis

Awarded Award Notice Posted

Solicitation number
PHS2025-1
Agency
National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
Awarded
to L2 Diagnostics LLC
Set-aside
Total Small Business

Opportunity facts

Contract number
75N93025C00024 Federal contract award
NAICS code
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Place of performance
New Haven, Connecticut 06525, United States
Points of contact

Notice details come from SAM.gov. Updated .

About this opportunity

The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, has awarded contract 75N93025C00024 to L2 DIAGNOSTICS LLC for the development of a therapeutic vaccine platform designed to boost immune responses in Tuberculosis. The contract was awarded on August 1, 2025, with a total value of $599,471.00. This award represents a Total Small Business set-aside opportunity, indicating the agency's commitment to supporting small business participation in this critical public health research initiative. The contract focuses on advancing therapeutic vaccine technology specifically targeting tuberculosis treatment through enhanced immune system responses.

Notice text

Awarded contract 75N93025C00024 to L2 DIAGNOSTICS LLC for 599471.00 on 2025-08-01.

Notice history

And 4 more award notices.

On GovTribe

Work this opportunity on GovTribe

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity